Antitumor Effects of Interferon-Alpha on Cell Growth and Metastasis in Human Nasopharyngeal Carcinoma

Liu, X.; Lu, Jianhua; He, Ming; Li, Z.; Zhang, B.; Zhou, Liye; Li, Q.; Li, G.; Wang, L.; Tian, Wendong; Peng, Yong-jian; Li, X.-P.

doi:10.2174/156800912800673293

Cited by 19 publications

(13 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As a multifunctional cytokine, IFN-α intervenes in tumour cell proliferation and apoptosis, and has been used in the treatment of various malignancies. A previous study determined that cell growth was inhibited by treatment with recombinant human IFN-α1b in human nasopharyngeal carcinoma ( 15 ). IFN-α markedly inhibits the growth of the pheochromocytoma PC12 line and increases apoptosis ( 16 ).…”

Section: Discussionmentioning

confidence: 99%

“…Data have suggested that the antitumor effects of immunotherapeutic drugs are associated with the cell cycle. A previous study demonstrated that T-cells were arrested in the G1-phase by recombinant human IFN-α1b in human nasopharyngeal carcinoma ( 15 ). Maeda et al ( 14 ) also reported that IFN-α induces cell cycle arrest in the G0/G1 phase in the HuH7 hepatocellular carcinoma cell line.…”

Section: Discussionmentioning

confidence: 99%

“…Interferon (IFN)-α is an immunotherapeutic agent generated predominantly by monocytes and macrophages, which elicit beneficial effects on human health in a variety of ways. Previous studies revealed that IFN-α modulates the immune response ( 13 ), induces apoptosis ( 14 ) and directly inhibits the proliferation ( 15 , 16 ) and differentiation of tumour cells ( 17 ). As a type I IFN, IFN-α has been used clinically.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo

Chen

Liang

Wáng

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Novel therapeutic strategies to improve clinical efficacy in patients with renal cell carcinoma (RCC) are required. The possibility of combination therapy with Lycium barbarum polysaccharides (LBP) and recombinant interferon (IFN)-α2b remains to be elucidated in RCC. The present study investigated the putative synergistic immunotherapeutic roles of LBP and IFN-α2b against RCC in vitro and in vivo. The mouse RCC cell line, Renca, was used for in vitro experiments. Treatment of the cells with a combination of LBP and IFN-α2b markedly inhibited cell proliferation, retarded cell cycle growth and promoted apoptosis in the Renca cells. Western blot analysis revealed that LBP and IFN-α2b synergistically downregulated the expression levels of cyclin D1, c-Myc and Bcl-2, and upregulated the expression of the antiapoptotic protein, Bax. Myeloid-derived suppressor cells (MDSCs) were markedly upregulated during tumour progression and promoted tumour growth by inhibiting the T-cell-mediated immune response. In vivo, a marked reduction in the MDSC ratio and tumour volume was observed in a group receiving combined treatment with LBP and IFN-α2b in a xenograft tumour model. In conclusion, the present study suggested that the combination of LBP and IFN-α2b is likely to be more effective in treating murine RCC compared with the less pronounced immunotherapeutic effects of administering LBP or IFN-α2b alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo

Chen

Liang

Wáng

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

show abstract

“…HuIFN-αN3, a type I interferon, is a multisubtype protein (8,9) with antiviral, antiproliferative, and antitumour activity (10). It has been used clinically in the treatment of various cancers for over 30 years (11).…”

Section: Abstract: Antiproliferative Activity; Antitumour Activity; mentioning

confidence: 99%

The influence of royal jelly and human interferon-alpha (HuIFN-αN3) on proliferation, glutathione level and lipid peroxidation in human colorectal adenocarcinoma cells in vitro / Vpliv matičnega mlečka in humanega interferona-alfa (HuIFN-αN3) na proliferacijo, nivo glutationa in na preoksidacijo lipidov v humanih kolorektalnih adenokarcinomskih celicah in vitro

Filipič

Gradišnik

Rihar

et al. 2015

Archives of Industrial Hygiene and Toxicology

View full text Add to dashboard Cite

Among royal jelly's (RJ) various biological activities, its possible antitumour activity deserves particular attention. The purpose of this study was to investigate the influence of RJ, its bioactive component 10-hydroxy-2-decenoic acid (10-HDA), and human interferon-alpha (HuIFN-αN3) on the proliferation of human colorectal adenocarcinoma cells (CaCo-2), and ascertain their effect on intracellular glutathione (GSH) level and lipid peroxidation. We studied the antiproliferative (AP) activity of RJ [(0.1 g/10 mL phosphate buffer saline (PBS)], HuIFN-αN3 (1000 I.U. mL , and their different combinations, in the ratio 1:1, 1:2, and 2:1 on CaCo-2 cells. The GSH level was measured by glutathione assay. The lipid peroxidation was measured by malondialdehyde (MDA) assay. Single RJ had a low AP activity: 2.0 (0.5 mg mL -1 ). HuIFN-αN3 had an AP activity of 2.5 (208.33 I.U. mL -1 ), while 10-HDA had an AP activity of 1.5 (37.5 μmol mL). The highest AP activity of 3.8 was obtained when RJ and HuIFN-αN3 were applied at the ratio 2:1. In that combination the level of GSH was 24.9±2.4 nmol g -3 of proteins (vs. 70.2±3.2 nmol g -3 in the control) and the level of MDA was 72.3±3.1 nmol g -3 (vs. 23.6±9.1 nmol g -3 in the control). It is generally assumed that 10-HDA, an important constituent of RJ, together with HuIFN-αN3, is responsible for the inhibition of CaCo-2 cells proliferation in vitro. In our study, however, RJ and HuIFN-αN3 applied at 2:1 decreased the level of GSH the most and significantly increased lipid peroxidation via MDA in CaCo-2 cells. Future studies should show whether these GSH-and MDA-related activities of RJ, HuIFN-αN3, 10-HDA, and their combinations may decrease the tumorigenicity index and tumorigenic potential of various tumour cells in vitro. KEY WORDS: antiproliferative activity; antitumour activity; CaCo-2 cells; 10-hydroxy-2-decenoic acid; malondialdehydeRoyal jelly (RJ) is a milky material secreted by the hypopharyngeal and mandibular glands of young worker bees between the sixth and twelfth day of their life. It is food exclusively for the queen honey bee (Apis mellifera) larva, which leads to the development of a sexually mature queen bee (1, 2). Chemically, RJ comprises water (50-60 %), different proteins (18.0 %), carbohydrates (15.0 %), lipids (3-6 %), mineral salts (1.5 %), and vitamins, together with a large number of bioactive substances, such as 10-hydroxy-2-decenoic (10-HDA) acid (3). RJ exhibits various immunomodulatory and antiproliferative properties, as well as possible antitumour activity. It also contains different antibacterial proteins like 350-kDa protein stimulating the proliferation of human monocytes (4-6). In addition, the RJ Protein 30 fraction exhibits a clear cytotoxic effect on HeLa cells by decreasing the initial cell population by 50 % at the end of treatment (7).Impact of royal jelly and HuIFN-αN3 on proliferation, glutathione, and lipid peroxidation in human colorectal adenocarcinoma cells in vitro Arh Hig Rada Toksikol 2015;66:269-274

show abstract

“…It has dual effects of anti-virus and immune regulation (6,7). Recombinant human interferon alpha 1b (rhIFN a 1b, Hapgen®) is a type of genetic engineering interferon developed in China (8), and rhIFNα1b has been used for the treatment of chronic viral hepatitis B, hand, foot and mouth disease and Epstein-Barr virus (EBV) infection (9)(10)(11). In this study, we investigated the effects of rhIFNα1b and other factors on subsequent wheezing in infants diagnosed with viral pneumonia, wheezy bronchitis, and bronchiolitis.…”

Section: Introductionmentioning

confidence: 99%

A Multicentre Preliminary Study of the Effect of Recombinant Human Interferon α1b Treatment of Infants Hospitalized with Lower Respiratory Tract Infection on Subsequent Wheezing

Lei¹,

Zhang²,

Cheng-xiu³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: To investigate the impact of recombinant human interferon α1b (rhIFNα1b) treatment of infants hospitalized with lower respiratory tract infections on subsequent wheezing.Methods: The clinical data of infants in 19 hospitals with viral pneumonia, wheezy bronchitis, or bronchiolitis were retrospectively reviewed from June 2009 to June 2015 (age, gender, diagnosis, the use of rhIFNα1b when in hospital). Age at follow-up, birth weight, gestation age, childhood and family history of allergy, feeding history, family environment, and the number of wheezing episodes within the last year were obtained by telephone and questionnaires. Based on the use of rhIFNα1b in hospital, the subjects were divided into two groups: the rhIFNα1b treatment group (253 cases) and the control group (287 cases). A comparison was made between the two groups in terms of wheezing episodes within the last year. Based on the number of wheezing episodes within the last year, the subjects were divided into two groups, the wheezing group (95 cases) and the non-wheezing group (445 cases). Comparisons were made between the 2 groups in terms of age, diagnosis, the use of rhIFNα1b in hospital, gender, age at follow-up, birth weight, gestation age, childhood and family history of allergy, feeding history, and family environment. If the result of single factor comparison showed that P was <0.05, the indicators were analysed by binary logistic regression. The receiver operator characteristic (ROC) curve was drawn to evaluate the prediction ability of logistic regression models.Results: (1) Of a total of 813 cases for which follow-up data were available, 273 cases were excluded because of incomplete questionnaires, a dosage of rhIFN a1 b < 1 ug/kg.d or a treatment duration < 3 days, a date in hospital beyond the scope of the follow-up, or because the patient’s age when in hospital was > 3 years old. Finally, 540 patients were included in the analysis.(2) A total of 95 (17.6%) out of 540 cases had experienced wheezing episodes within the last year; 35 (13.8%) out of 253 cases that were treated with rhIFN a1 b and 60 cases (20.9%) out of 287 cases without rhIFN a1 b treatment had wheezing episodes within the last year. The difference in wheezing episodes within the last year between the rhIFNα1b treatment group and the control group was statistically significant (P=0.031). (3)The result of single factor regression indicated that the differences between the two groups of wheezing and non-wheezing in terms of age, the use of rhIFNα1b in hospital, a childhood and family history of allergy, housing situation, and feeding history were all statistically significant (all P<0.05). The result of binary logistic regression showed that a childhood history of allergy (OR=2.14, P=0.004), no use of rhIFNα1b therapy (OR=1.70, P=0.028) and living in a crowded house (OR=1.92, P=0.012) were risk factors of subsequent wheezing. Breastfeeding (OR=0.44, P=0.008) and an age of £1year old at the time of hospitalization (OR=0.58, P=0.024) were protective factors. The area under the ROC curve was 0.68, P=0.00, which indicated that the regression model had greater than medium diagnostic accuracy. Conclusions: Early use of rhIFNα1b treatment for infants hospitalized with lower respiratory tract infections and breastfeeding could prevent subsequent wheezing. An atopic constitution and living in a crowded house could promote subsequent wheezing.

show abstract

Antitumor Effects of Interferon-Alpha on Cell Growth and Metastasis in Human Nasopharyngeal Carcinoma

Cited by 19 publications

References 48 publications

Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo

Synergistic immunotherapeutic effects of Lycium barbarum polysaccharide and interferon-α2b on the murine Renca renal cell carcinoma cell line in vitro and in vivo

A Multicentre Preliminary Study of the Effect of Recombinant Human Interferon α1b Treatment of Infants Hospitalized with Lower Respiratory Tract Infection on Subsequent Wheezing

Contact Info

Product

Resources

About